Nielsen: Vape Sales Decline in U.S., Vuse Market Share Slightly Rising to 42.2%

Market by 2FIRSTS.ai
Mar.06
Nielsen: Vape Sales Decline in U.S., Vuse Market Share Slightly Rising to 42.2%
According to Journalnow, e-cigarette sales in the US have dropped 13.9%, with Vuse by R.J. Reynolds gaining market share.

According to a recent report by Journalnow, data released by Nielsen Convenience Store shows that overall e-cigarette sales in the United States have decreased by 13.9%.

 

Among them, the market share of the best-selling e-cigarette brand Vuse, owned by British American Tobacco subsidiary R.J. Reynolds, has gradually increased from 42% to 42.2%; while the second-ranked JUUL's market share remains unchanged at 24.2%; the market share of NJoy, acquired by Ascent Industries, has reached 3.2%; and the market share of blu eCigs, owned by Imperial Tobacco subsidiary Fontem Ventures, has decreased from 1.2% to 1.1%.

 

In 2019, JUUL held a market share of 74.6% in the e-cigarette market in the United States. However, a series of regulatory actions have led to a reduction in product availability and a decrease in consumer demand.

 

British American Tobacco and Imperial Brands are urging the Food and Drug Administration (FDA) to crack down on the illegal synthetic nicotine e-cigarette products in the US tobacco market. The two companies estimate that these synthetic tobacco products account for half of the entire e-cigarette market in the United States.

 

The Nielsen report primarily focuses on large chain stores, while for small chain stores, the organization relies on trend extrapolation.

 

Notice

1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.

2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.

3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.

Copyright

This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.

This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.